BofA update shows where active managers are putting money
EDEN PRAIRIE, Minn. - NeuroOne Medical Technologies Corporation (NASDAQ:NMTC), whose stock has surged over 42% in the past week, has received a notice of allowance from the U.S. Patent and Trademark Office for a patent titled "Methods for Making Probe Devices and Related Devices," the company announced Wednesday. According to InvestingPro data, the $51 million market cap company currently trades above its Fair Value.
The patent application (17/392,773) covers novel methods of manufacturing neural probe devices, including specific steps for component arrangement and electrode contact material deposition. The company expects the patent to be officially issued in the coming months. While NeuroOne’s revenue has grown by 54% over the last twelve months, InvestingPro analysis reveals the company faces profitability challenges with negative gross margins.
"One of the key aspects with this patent relates to the novel method of electrode material deposition for all of our electrodes that are both commercially available and in development," said Dave Rosa, Chief Executive Officer of NeuroOne.
This addition strengthens NeuroOne’s intellectual property portfolio, which now includes 17 issued and pending patents in the United States and internationally. These patents cover various thin-film electrode technologies, including neural and spinal cord electrodes with structures designed to optimize functionality while minimizing profile.
NeuroOne develops minimally invasive solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation for patients with neurological disorders such as epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries.
The information in this article is based on a company press release statement. For deeper insights into NeuroOne’s financial health, valuation metrics, and growth prospects, including 12 additional ProTips and comprehensive analysis, visit InvestingPro’s detailed research report.
In other recent news, NeuroOne Medical Technologies Corporation reported its first-quarter 2025 earnings, exceeding expectations for earnings per share (EPS) but falling short on revenue. The company’s EPS was reported at -$0.07, which surpassed the forecast of -$0.09. However, revenue was $1.4 million, notably below the anticipated $2.4 million. In another development, NeuroOne received a notice of allowance from the U.S. Patent and Trademark Office for a patent concerning its neural probe technology. The patent covers methods for manufacturing neural probe devices, focusing on component arrangement and electrode contact material deposition. NeuroOne expects the patent to be formally issued in the coming months. These recent developments highlight ongoing advancements and challenges for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.